Samsung-PolyPeptide Tender Offer Cooling-Off Period Continues Through September 15; Main Offer Period September 15 to October 12
The Samsung Biologics tender offer for PolyPeptide Group AG (announced July 20 at CHF 44.31 per share, CHF 1.46 billion / $1.8 billion, 40% premium) continued through Sunday September 6, 2026 in the 10 SIX Swiss Exchange trading-day cooling-off period that began September 1 following Samsung Peptide AG's August 31 publication of the formal tender offer prospectus. Under Swiss takeover law, the main offer period commences Tuesday September 15, 2026 and runs through October 12, 2026 at 4 p.m. Swiss time. Closing conditions include a 66⅔% minimum acceptance threshold plus customary regulatory approvals. Draupnir Holding B.V. (approximately 55.65% of PolyPeptide shares outstanding) has committed to tender all of its shares. Transaction close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide, integrating the Malmö, Limhamn, Strasbourg, Braine-l'Alleud, and Torrance sites into Samsung's Incheon multi-modality footprint. The transaction will consolidate one of the top three global peptide CDMO capacity positions alongside Bachem and CordenPharma.